Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.3600 +0.1500 (+71.43%)
Streaming Delayed Price Updated: 1:16 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 Next >
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
Lexaria's Technology Proven to Deliver Oral THC More Effectively
- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via CannabisNewsWire
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
- DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Exposures Intellectual Property Supply Chain
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Receives US$3,817,643 From Warrant Exercises
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Death Intellectual Property
Exposures Animal Testing COVID-19 Death
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Receives Patent Protection in Japan
New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Announces 2021 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing Intellectual Property
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Commences Human Clinical Hypertension Study
- Study to examine DehydraTECHTM CBD's ability to control blood pressure - First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
- DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Exposures Intellectual Property Supply Chain
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.